Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

All About the New Ketamine Trial at the University of Otago

Apr 12 • 3 min read

Depression remains one of the most challenging mental health conditions, affecting millions worldwide with varying degrees of severity. Traditional treatments like psychotherapy and antidepressants are effective for many, yet a subset of patients find these methods inadequate. This has led to a burgeoning interest in alternative treatments, among which ketamine therapy stands out due to…

Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research

Apr 8 • 3 min read

Missouri’s legislative body, the House of Representatives, has recently endorsed a budget legislation earmarking $10 million of the state’s opioid settlement proceeds for research grants. However, these aren’t ordinary grants. Their purpose is to delve into the potential of psilocybin as a remedy for opioid use disorder, an issue that’s currently casting a shadow over…

Filament Health Nets $2.1M in Revenue in 2023

Apr 4 • 3 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) has recently shared its financial achievements for both the final quarter and the entire fiscal year ending December 31, 2023. This period has been notable for the biotech firm specializing in the development of natural psychedelic drugs, as it reported promising increases in revenue and a…

FSD Pharma Cuts Annual Losses to $18Million; Will Need More Capital to Develop

Apr 4 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE)(CSE: HUGE) recently disclosed its audited financial results for the fourth quarter and the entirety of the fiscal year ending December 31, 2023. Currently, the company has not generated any revenue. For the year 2023, FSD Pharma reported a net loss of $18.2 million, which is an improvement from the previous…

Alberta Blue Cross Moves Toward Covering Psychedelic-Assisted Therapy

Apr 4 • 3 min read

Alberta Blue Cross’s recent decision to include psychedelic-assisted therapy in their healthcare coverage marks a transformative moment in the perception and acceptance of psychedelic substances within mental health treatment paradigms. This groundbreaking initiative not only positions Alberta as the pioneering Canadian province to formalize insurance coverage for such treatments but also paves the way for…

Pages: 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253